Kazia Therapeutics - GDC-0084 Phase II to begin shortly
Novogen has changed its name to Kazia Therapeutics and undertaken a 10:1 share consolidation following shareholder approval in November. It has also out-licensed its preclinical super-benzopyran development programme, and has added a dose optimisation lead-in component to the Phase II trial of GDC-0084 in glioblastoma, which is expected to commence in early 2018. Although the more focused pipeline and longer Phase II trial for GDC-0084 prompts us to trim our valuation to between A$69m and A$127m, we believe the changes will be positive in the long run, increasing the chance of success in the GDC-0084 development programme.Kazla Therapeutics is a global oncology biotechnology company, focused on developing cancer treatments. Co. has two main drug technology platforms: super-benzopyran and anti-tropomyosins (ATM). Within those platforms, Co. has three drug candidates under development: Cantrixil (TRX-E-002-1), for women with later-stage ovarian cancer; Anisina (ATM-3507), which is designed to enhance chemotherapy agents such as taxanes and vinca alkaloids, which are used across a range of cancer treatments including lung, prostate, colon, gastric, prostrate, pancreatic and breast cancer, as well as many childhood cancers; and Trilexium (TRX-E-009-1), for treatment of renal cancer and several childhood cancers.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.